A share price of Galectin Therapeutics Inc [GALT] is currently trading at $4.16, up 1.96%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GALT shares have gain 4.26% over the last week, with a monthly amount drifted -24.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Buy rating on August 13, 2020, and elevated its price target to $12. On February 13, 2019, B. Riley FBR initiated with a Buy rating and assigned a price target of $11 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $10 on December 07, 2017. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $6 on November 28, 2017. In a note dated March 30, 2017, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $3.50.
Galectin Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.07 and $7.13. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $4.16 at the most recent close of the market. An investor can expect a potential return of 164.42% based on the average GALT price forecast.
Analyzing the GALT fundamentals
Gross Profit Margin for this corporation currently stands at 0.17% with Operating Profit Margin at -693.06%, Pretax Profit Margin comes in at -1036.19%, and Net Profit Margin reading is -1036.19%. To continue investigating profitability, this company’s Return on Assets is posted at -2.9, Equity is 0.33 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.05 points at the first support level, and at 3.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.23, and for the 2nd resistance point, it is at 4.31.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Galectin Therapeutics Inc [NASDAQ:GALT] is 0.09. In addition, the Quick Ratio stands at 0.09 and the Cash Ratio stands at 0.08.
Transactions by insiders
Recent insider trading involved Jamil Khurram, Officer, that happened on Dec 31 ’25 when 8125.0 shares were purchased. Director, ELDRED KARY completed a deal on Dec 23 ’25 to buy 700.0 shares. Meanwhile, Director FREEMAN KEVIN D bought 5500.0 shares on Dec 23 ’25.
